Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells $1,002,840.96 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 30,426 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $32.96, for a total value of $1,002,840.96. Following the completion of the sale, the insider now owns 149,647 shares of the company’s stock, valued at approximately $4,932,365.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oxana Beskrovnaya also recently made the following trade(s):

• On Thursday, May 16th, Oxana Beskrovnaya sold 2,705 shares of Dyne Therapeutics stock. The stock was sold at an average price of $28.27, for a total transaction of $76,470.35.
• On Thursday, March 7th, Oxana Beskrovnaya sold 2,373 shares of Dyne Therapeutics stock. The shares were sold at an average price of $25.85, for a total transaction of $61,342.05.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $31.22 on Friday. The firm has a market capitalization of $2.73 billion, a P/E ratio of -7.86 and a beta of 1.00. The stock has a 50 day moving average price of $27.12 and a 200-day moving average price of $20.66. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $35.98.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, meeting the consensus estimate of ($0.81). On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DYN. Wetzel Investment Advisors Inc. purchased a new stake in Dyne Therapeutics in the first quarter worth about $28,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Dyne Therapeutics by 58.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after purchasing an additional 3,092 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Dyne Therapeutics by 95.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock worth $83,000 after buying an additional 4,552 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after buying an additional 5,541 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in Dyne Therapeutics by 10.7% during the third quarter. Principal Financial Group Inc. now owns 15,229 shares of the company’s stock valued at $136,000 after buying an additional 1,476 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of analyst reports. HC Wainwright boosted their price objective on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, May 20th. Piper Sandler boosted their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Chardan Capital increased their price objective on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday. Oppenheimer reissued an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a research note on Monday, May 6th. Finally, Stifel Nicolaus upped their target price on Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.78.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.